TEVA – Teva Pharmaceutical Industries Limited
TEVA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
2.81
Margin Of Safety %
-17
Put/Call OI Ratio
0.35
EPS Next Q Diff
EPS Last/This Y
0.91
EPS This/Next Y
0.93
Price
35.35
Target Price
42.12
Analyst Recom
1.23
Performance Q
-1.81
Upside
-41.6%
Beta
0.87
Ticker: TEVA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | TEVA | 32.18 | 0.37 | 0.10 | 454221 |
| 2026-07-14 | TEVA | 31.82 | 0.36 | 0.11 | 454797 |
| 2026-07-15 | TEVA | 31.55 | 0.36 | 0.27 | 455138 |
| 2026-07-16 | TEVA | 32.24 | 0.36 | 3.50 | 454153 |
| 2026-07-17 | TEVA | 32.03 | 0.35 | 0.51 | 453579 |
| 2026-07-20 | TEVA | 31 | 0.38 | 0.14 | 408629 |
| 2026-07-21 | TEVA | 31.36 | 0.37 | 0.63 | 412615 |
| 2026-07-22 | TEVA | 30.04 | 0.37 | 1.19 | 412724 |
| 2026-07-23 | TEVA | 31.17 | 0.37 | 0.18 | 413685 |
| 2026-07-24 | TEVA | 30.84 | 0.37 | 0.64 | 415449 |
| 2026-07-27 | TEVA | 31.08 | 0.37 | 0.17 | 411670 |
| 2026-07-28 | TEVA | 31.65 | 0.37 | 0.11 | 412759 |
| 2026-07-29 | TEVA | 34.74 | 0.37 | 0.14 | 417292 |
| 2026-07-30 | TEVA | 34.98 | 0.39 | 5.22 | 415971 |
| 2026-07-31 | TEVA | 35.02 | 0.35 | 0.39 | 406174 |
| 2026-08-03 | TEVA | 34.43 | 0.35 | 0.27 | 400039 |
| 2026-08-04 | TEVA | 34.43 | 0.35 | 0.26 | 404389 |
| 2026-08-05 | TEVA | 34.72 | 0.35 | 0.65 | 404645 |
| 2026-08-06 | TEVA | 34.8 | 0.35 | 0.34 | 405599 |
| 2026-08-07 | TEVA | 35.35 | 0.35 | 0.11 | 407394 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | TEVA | 32.19 | -44.9 | -622.5 | 2.22 |
| 2026-07-14 | TEVA | 31.81 | -54.2 | -625.1 | 2.22 |
| 2026-07-15 | TEVA | 31.55 | -64.5 | -597.7 | 2.22 |
| 2026-07-16 | TEVA | 32.24 | -64.5 | -568.8 | 2.22 |
| 2026-07-17 | TEVA | 32.03 | -64.5 | -608.5 | 2.22 |
| 2026-07-20 | TEVA | 31.00 | -64.5 | -643.2 | 2.22 |
| 2026-07-21 | TEVA | 31.35 | -64.5 | -617.8 | 2.22 |
| 2026-07-22 | TEVA | 30.14 | -74.7 | -634.0 | 2.21 |
| 2026-07-23 | TEVA | 31.18 | -74.7 | -583.8 | 2.21 |
| 2026-07-24 | TEVA | 30.82 | -83.5 | -594.3 | 2.16 |
| 2026-07-27 | TEVA | 31.08 | -83.5 | -584.0 | 2.16 |
| 2026-07-28 | TEVA | 31.67 | -83.5 | -561.1 | 2.16 |
| 2026-07-29 | TEVA | 34.69 | -83.5 | -448.1 | 2.16 |
| 2026-07-30 | TEVA | 35.41 | -83.5 | -548.4 | 2.16 |
| 2026-07-31 | TEVA | 35.00 | -16.0 | -43.6 | 2.16 |
| 2026-08-03 | TEVA | 34.44 | -16.0 | -56.3 | 2.16 |
| 2026-08-04 | TEVA | 34.44 | -16.0 | -56.3 | 2.16 |
| 2026-08-05 | TEVA | 34.69 | -10.1 | -2.5 | 2.14 |
| 2026-08-06 | TEVA | 34.81 | -10.1 | -7.8 | 2.14 |
| 2026-08-07 | TEVA | 35.35 | -10.1 | 4.7 | 2.14 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | TEVA | -95.13 | -1.76 | 2.75 |
| 2026-07-14 | TEVA | -95.13 | -1.76 | 2.75 |
| 2026-07-15 | TEVA | -95.13 | -1.76 | 2.75 |
| 2026-07-16 | TEVA | -95.13 | -1.76 | 2.75 |
| 2026-07-17 | TEVA | -95.13 | -1.76 | 2.75 |
| 2026-07-20 | TEVA | -95.13 | -1.88 | 2.75 |
| 2026-07-21 | TEVA | -95.13 | -1.88 | 2.75 |
| 2026-07-22 | TEVA | -95.13 | -1.88 | 2.75 |
| 2026-07-23 | TEVA | -95.13 | -1.88 | 2.75 |
| 2026-07-24 | TEVA | -95.13 | -1.88 | 2.75 |
| 2026-07-27 | TEVA | -95.13 | -0.91 | 2.81 |
| 2026-07-28 | TEVA | -95.13 | -0.91 | 2.81 |
| 2026-07-29 | TEVA | -95.13 | -0.91 | 2.81 |
| 2026-07-30 | TEVA | -95.13 | -0.91 | 2.81 |
| 2026-07-31 | TEVA | -95.13 | -0.91 | 2.81 |
| 2026-08-03 | TEVA | -95.13 | -1.44 | 2.81 |
| 2026-08-04 | TEVA | -95.13 | -1.44 | 2.81 |
| 2026-08-05 | TEVA | -95.21 | -1.44 | 2.81 |
| 2026-08-06 | TEVA | -95.21 | -1.44 | 2.81 |
| 2026-08-07 | TEVA | -95.21 | -1.44 | 2.81 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
0.7
Avg. EPS Est. Next Quarter
0.74
Insider Transactions
-95.21
Institutional Transactions
-1.44
Beta
0.87
Average Sales Estimate Current Quarter
4226
Average Sales Estimate Next Quarter
4220
Fair Value
29.41
Quality Score
63
Growth Score
54
Sentiment Score
64
Actual DrawDown %
5.3
Max Drawdown 5-Year %
-43.7
Target Price
42.12
P/E
59.46
Forward P/E
11.53
PEG
2.1
P/S
2.36
P/B
5.31
P/Free Cash Flow
28.04
EPS
0.59
Average EPS Est. Cur. Y
2.14
EPS Next Y. (Est.)
3.07
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
4.01
Relative Volume
0.73
Return on Equity vs Sector %
-18.2
Return on Equity vs Industry %
2.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.08
EBIT Estimation
4.7
◆
TEVA
Healthcare
$35.36
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
62
Range 1M
87.9%
Sup Dist
2.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-31.7%
EPS NY
53.3%
52W%
89.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+100.7% upside
Upside
+100.7%
Quality
63
MoS
-17%
TEVA — P/E HistoricalDrug Manufacturers - Specialty & Generic
Teva Pharmaceutical Industries Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 31173
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
TEVA
Latest News
—
Caricamento notizie per TEVA…
stock quote shares TEVA – Teva Pharmaceutical Industries Limited Stock Price stock today
news today TEVA – Teva Pharmaceutical Industries Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TEVA – Teva Pharmaceutical Industries Limited yahoo finance google finance
stock history TEVA – Teva Pharmaceutical Industries Limited invest stock market
stock prices TEVA premarket after hours
ticker TEVA fair value insiders trading